Drug Trials Snapshots: HERNEXEOS
Similar Posts
Shopaax.com – 626291 – 07/01/2022
Interstate Commerce/Food/AdulteratedGuidance Documents for Rare Disease Drug Development
Guidance Documents for Rare Disease Drug DevelopmentEndo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling
Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) due to potential product carton strength mislabeling.FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine
FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug ClozapineSTAQ Pharma of Ohio, LLC. Columbus, OH. 483 issued 05/16/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 05/16/2025
Short Title (70 char) STAQ Pharma of Ohio, LLC. Columbus, OH. 483 issued 05/16/2025
FEI Number 3025336457
Firm Name STAQ Pharma of Ohio, LLC
Record Type 483
State OH
Establishment Type Outsourcing FacLEESAR, Inc. Fort Myers, FL. 483 issued 05/09/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 05/09/2025
Short Title (70 char) LEESAR, Inc. Fort Myers, FL. 483 issued 05/09/2025
FEI Number 3010166880
Firm Name LEESAR, Inc.
Record Type 483
State FL
Establishment Type Outsourcing Facility